W. Tyler Turchan - Search Results

Year	Number of Results
2019	1
2020	4
2021	8
2022	7
2023	2
2024	1

1

Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. Turchan WT, et al. J Urol. 2022 Jun;207(6):1245. doi: 10.1097/JU.0000000000002443.02. Epub 2022 Mar 3. J Urol. 2022. PMID: 35236091 No abstract available.

2

Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era.

Turchan WT, Pitroda SP, Weichselbaum RR. Turchan WT, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):581-586. doi: 10.1016/j.ijrobp.2022.04.015. Epub 2022 Oct 13. Int J Radiat Oncol Biol Phys. 2022. PMID: 36244394 No abstract available.

3

Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold.

Turchan WT, Pitroda SP, Weichselbaum RR. Turchan WT, et al. Int J Mol Sci. 2021 Sep 3;22(17):9573. doi: 10.3390/ijms22179573. Int J Mol Sci. 2021. PMID: 34502479 Free PMC article. Review.

4

The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review.

Turchan WT, Chmura SJ. Turchan WT, et al. Ann Palliat Med. 2021 May;10(5):6028-6044. doi: 10.21037/apm-20-1528. Epub 2021 Jan 4. Ann Palliat Med. 2021. PMID: 33440982 Free article. Review.

5

Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus.

Turchan WT, Pitroda SP, Weichselbaum RR. Turchan WT, et al. Clin Cancer Res. 2021 Oct 1;27(19):5188-5194. doi: 10.1158/1078-0432.CCR-21-0145. Clin Cancer Res. 2021. PMID: 34140404 Review.

6

Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.

Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. Turchan WT, et al. J Urol. 2022 Jun;207(6):1236-1245. doi: 10.1097/JU.0000000000002443. Epub 2022 Jan 20. J Urol. 2022. PMID: 35050703

7

Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status.

Turchan WT, Liauw SL. Turchan WT, et al. Semin Radiat Oncol. 2021 Oct;31(4):349-360. doi: 10.1016/j.semradonc.2021.02.007. Semin Radiat Oncol. 2021. PMID: 34455990 Review.

8

Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy.

Turchan WT, Pitroda SP, Weichselbaum RR. Turchan WT, et al. Neoplasia. 2022 May;27:100782. doi: 10.1016/j.neo.2022.100782. Epub 2022 Mar 15. Neoplasia. 2022. PMID: 35303578 Free PMC article.

9

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.

Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. Gutiontov SI, et al. Sci Rep. 2021 Oct 8;11(1):20059. doi: 10.1038/s41598-021-99524-1. Sci Rep. 2021. PMID: 34625620 Free PMC article.

10

Patterns of Care and Survival Outcomes for Odontogenic Cancers.

Rooney MK, Korpics MC, Turchan WT, Callahan N, Koshy M, Spiotto MT. Rooney MK, et al. Laryngoscope. 2021 May;131(5):E1496-E1502. doi: 10.1002/lary.29173. Epub 2020 Nov 2. Laryngoscope. 2021. PMID: 33135786 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year